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Abstract 
 
The iron is an essential element for many biological reactions carried out by 
living systems. A tight regulation of the systemic iron homeostasis is crucial to avoid 
pathological conditions of iron deficiency or overload. Juvenile Hemochromatosis is an 
early-onset inherited disorder associated to an iron overload caused by mutations on the 
hepcidin gene or in the gene encoding hemojuvelin (HJV). HJV is a 
glycosylphosphatidylinositol (GPI)-linked membrane protein shown to be a co-receptor 
for a class of ligands called bone morphogenetic proteins (BMPs), which trigger a 
response to the iron increase by activating the hepcidin transcription. Thus, HJV is 
involved on iron homeostasis through regulation of hepcidin transcription levels. 
A better knowledge of the mechanisms implicated in HJV gene expression is 
crucial to understand its role in the iron homeostasis. The 5’ leader sequence of the 
human HJV mRNA has two upstream AUGs (uAUGs) that share the same codon stop, 
forming two upstream open reading frames (uORFs) with 28 and 19 codons. To 
evaluate the effect of these uORFs in the translational regulation of HJV, reporter 
constructs containing several HJV 5’ leader sequences fused to the firefly Luciferase 
cistron, were tested in HeLa and HepG2 cells. Luciferase activity was measured by 
luminometry assays and the corresponding mRNA levels, quantified by real-time 
reverse transcription quantitative polymerase chain reaction (RT-qPCR).  
The results revealed that the HJV uORFs decrease the translational efficiency of 
the main ORF in about 6-fold. Furthermore, we have observed that the uAUGs suffers 
low leaky scanning which contributes to the translational repression of the main ORF. 
Thus, translation reinitiation is the main mechanism involved in the production of HJV 
protein. Aiming to further characterize the mechanism through which the HJV uORFs 
affect downstream translation, we have observed that the uORF2 encoded peptide seems 
to cause ribosomal stalling, which also prevents translation of the downstream main 
ORF. Together, these results produce a framework for understanding how human HJV 
gene expression is fine-tuned controlled during translation.   
 
Keywords: hemojuvelin (HJV), iron homeostasis, upstream open reading frames 
(uORFs), leaky scanning, translation reinitiation and ribosome stalling. 
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Sumário 
 
O ferro é um elemento essencial para muitas reacções biológicas envolvidas no 
funcionamento dos organismos. A regulação rigorosa da homeostase do ferro é crucial 
para evitar patologias relacionadas com a deficiência ou excesso de ferro no organismo. 
Nos casos em que a homeostase do ferro é perturbada podem ocorrer diversas 
patologias tais como a Hemocromatose Juvenil. Esta doença está associada ao excesso 
de ferro e é devida a mutações nos genes da hepcidina ou da hemojuvelina (HJV). A 
HJV é uma proteína de membrana com um domínio glicosilfosfatidilinositol (GPI) que 
tem sido caracterizada como um co-receptor de uma classe de ligandos denominados 
Bone Morphogenetic Proteins (BMPs) que desencadeiam uma resposta ao aumento dos 
níveis de ferro por activação da transcrição da hepcidina. Desta forma, a HJV é 
responsável pela regulação do metabolismo do ferro através da modelação da 
transcrição do gene da hepcidina. 
Um maior conhecimento dos mecanismos implicados na regulação da expressão 
da HJV seria fulcral para um melhor entendimento da importância desta na homeostase 
do ferro. A sequencia 5’ líder do mRNA da HJV humana possui dois AUGs a montante 
do AUG principal (uAUGs) que partilham o mesmo codão de terminação formando 
duas grelhas de leitura a montante da grelha de leitura principal (uORFs) com 28 e 19 
codões. De modo a avaliar o efeito destas uORFs na regulação da tradução da HJV 
foram testadas várias construções repórter, em células HeLa e HepG2, contendo a 
sequência 5’ líder do mRNA da HJV humana ligada ao cistrão da Luciferase do 
pirilampo. A actividade da Luciferase foi medida por luminometria e os 
correspondentes níveis de mRNA quantificados por reverse transcription quantitative 
polymerase chain reaction (RT-qPCR). 
Os resultados mostram que as uORFs presentes no transcrito da HJV diminuem 
a eficiência de tradução da ORF principal em cerca de 6 vezes. Além disso, foi 
verificado que os uAUGs sofrem pouco leaky scanning o que contribui para a repressão 
da tradução da ORF principal. Assim, a reiniciação da tradução é o principal mecanismo 
envolvido na produção da proteína da HJV. Visando uma melhor caracterização do 
mecanismo através do qual as uORFs da HJV afectam a tradução a jusante, verificou-se 
que a sequência peptídica codificada pela uORF2 parece ter a capacidade de bloquear o 
ribossoma o que impede a tradução da ORF principal. Juntos, estes resultados 
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contribuem para a compreensão de como a expressão do gene HJV é controlada durante 
o processo de tradução. 
 
Palavras-chave: hemojuvelina (HJV), homeostase do ferro, grelhas de leitura a 
montante da grelha de leitura principal (uORFs), leaky scanning, reiniciação da 
tradução e bloqueio do ribossoma. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
Abbreviations  
 
A adenine 
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DMT1 divalent metal transporter 1 
DNA  deoxyribonucleic acid 
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HepG2  human hepatocellular carcinoma cell line 
HH hereditary hemochromatosis  
HJV hemojuvelin  
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n  (any) nucleotide 
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1. Introduction 
 
1.1. The fundamentals of iron metabolism 
The iron, one of the essential micronutrients, is crucial for erythropoiesis, 
oxidative metabolism and cellular immune response [1]. Its ability to accept and donate 
electrons gives him its vital function, however, this characteristic can also be potentially 
toxic [2]. In solution, free iron can form highly reactive free radicals that lead to cell 
damage [2][3]. Thus, the iron homeostasis requires a tight regulation. 
The hemoglobin in the erythrocytes are responsible for oxygen transport and 
holds the vast majority (65-70 %) of the body iron [2]. Approximately 20% of the body 
iron is stored in the liver, macrophages of the reticuloendothelial system and bone 
marrow. The remaining percentage (10-15%) is found in myoglobin (within muscle 
fibres), enzymes and cytochromes [2].  
The iron lacks a mechanism for excretion. It is lost due to sloughed intestinal 
mucosal cells and blood losses [1][4]. Moreover, iron can be replenished by 
hemoglobin-derived iron from senescent red blood cells [5]. In this way, the regulation 
of dietary iron absorption plays a critical role in iron homoeostasis [3], depending on the 
stored iron, hypoxia, inflammation and rate of erythropoiesis [1]. 
The iron intestinal absorption is made by the divalent metal transporter 1 
(DMT1), present in the apical membrane of the enterocytes, which transports heme 
groups through the membrane (Figure 1) [6]. The Fe
2+
 inside the enterocyte is stored in 
ferritin or exported by ferroportin 1 across the basolateral membrane [1]. Ferroportin 1 
is also expressed in hepatocytes, reticuloendothelial macrophages and placental 
syncytiotrophoblasts (where it regulates iron entry into fetal circulation) [7]. Once iron 
is released into the blood, it binds to circulating transferrin, responsible for its transport 
to sites of use and storage [1][5]. Diferric transferrin (transferrin bound to two 
molecules of Fe
2+
) delivers iron to cells through binding to transferrin receptor 1 (TfR1) 
at the plasma membrane, creating receptor-ligand complexes and releasing iron into the 
cell where it can be deposited into ferritin [5].  
Hepcidin is the mediator of iron homoeostasis. This small peptide hormone 
secreted predominantly by hepatocytes increases in response to the augment of 
circulatory iron [8]. The secretion of hepcidin into the bloodstream allows the 
interaction with ferroportin 1, present in enterocytes basolateral membranes, regulating 
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the rate of iron absorption [1]. The binding of hepcidin to ferroportin promotes its 
phosphorylation, internalization and lysosomal degradation (Figure 1) [8]. Therefore, 
when serum hepcidin concentration increases, in cases of iron overload or 
infection/inflammation, the dietary-iron absorption and the macrophages degranulation 
decreases [4]. On the other hand, hepcidin levels decrease during iron deficiency and 
hypoxia, promoting more intestinal iron absorption and iron release from macrophages 
[4]. The importance of this tightly regulated iron homeostasis is evident from a number 
of pathological conditions in humans, including hemochromatosis. 
 
1.2. Hereditary Hemochromatosis and juvenile hemochromatosis  
Hereditary Hemochromatosis (HH) is a group of genetic disorders of iron 
overload [9]. The disruption of the mechanisms that regulate iron absorption leads to a 
progressive increase of total body iron and organ damage, particularly, the liver, heart 
and pancreas [10]. In every type of HH occurs an increase of intestinal iron absorption 
and a rapid iron release from macrophages (Figure 1) [11]. These events lead to an 
increase of ferritin in circulation causing more iron absorption through transferrin 
receptors, increasing the iron accumulation [10]. 
The HH is caused by mutations that affect hepcidin itself, the regulators of 
hepcidin (HFE, TfR2 and hemojuvelin (HJV)), or the hepcidin target ferroportin [11]. 
Therefore, each of the four types of HH is associated to a mutation on these genes. HH 
type 1 is related to mutations in HFE gene [12]. Mutations in two genes, HJV and 
hepcidin antimicrobial peptide (HAMP), induce respectively, the HH type 2A and 2B 
[12][13]. Mutations in TfR2 lead to HH type 3 whereas those of the ferroportin gene are 
associated to HH type 4 [12].  
Every type of HH is characterized by an intestinal hyperabsorption of iron. 
However, in Juvenile Hemochromatosis (HH type 2) a greater iron uptake, triggers an 
earlier and more acute phenotype [14]. Juvenile Hemocromatosis causes cardiac failure 
and endocrinopathy (particularly hypogonadism). This disorder usually appears in 
individuals under 30 years old, affecting both sexes [15]. The HJV gene, one of the 
genes affected by HH type 2, is responsible for hepcidin regulation and the study of the 
mechanisms involved in the regulation of its expression can help to better understand 
the causes of this illness.    
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Figure 1. Intestinal iron absorption and macrophages iron release under normal conditions or in 
Hemochromatosis. The iron absorption occurs in the enterocytes where the ferroportin allows the 
entrance of the iron into the organism. Hepcidin is the regulator of the iron absorption and macrophages 
iron release, keeping the serum levels according to the organism needs. In the conditions of 
Hemochromatosis, the levels of hepcidin are diminished or even absent, increasing the ferroportin on the 
cell surface resulting in a faster iron release. As a result, the intestinal iron absorption increases as well as 
the degranulation of the macrophages raising the serum levels of iron. Adapted from Donovan et al, 2006.  
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1.3. Hemojuvelin gene and its role in the iron homeostasis  
Hemojuvelin or HFE2 gene, located in 1q21 chromosome, was identified in 
2004 by Papanikolaou and colleagues. HJV is considered a bone morphogenetic protein 
(BMP) co-receptor of BMP signalling [13]. BMPs, members of the transforming growth 
factor b (TGFb) superfamily of cytokines, play an important role during development, 
being involved in proliferation, differentiation and apoptosis [16].  
HJV acts through the BMP signalling pathway in order to modulate the 
expression of hepcidin [17]. HJV binds to complexes of two type I and two type II BMP 
receptors (BMPR-I and II) and induces the phosphorylation of BMPR-I by BMPR-II 
(Figure 2). Consequently, this activated complex phosphorylates a subset of Smad 
proteins (Smads 1, 5 and 8) [17]. These phosphorilated Smads have the ability to bind to 
Smad4, creating a complex that migrates to the nucleus, binding itself to specific DNA 
motifs, regulating gene transcription [2]. Due to this process, HJV expression leads to 
an increase in hepcidin expression, demonstrating its fundamental role in systemic iron 
metabolism [2][13]. However, hepcidin synthesis can be inhibited by matriptase-2 that 
cleaves the HJV located in the membrane into fragments, presumably abolishing its 
function [18]. It is also important to mention that HJV acts only in cases of iron 
overload and not in inflammatory situations where hepcidin is also involved [19].  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Translation regulation of hepcidin by hemojuvelin. Hemojuvelin, a 
glycosylphosphatidylinositol (GPI)-linked membrane protein, acts as a bone morphogenetic protein 
(BMP) co-receptor and modulates hepcidin expression by stimulating BMP signalling. Upon binding by 
HJV, bone morphogenetic protein receptor II (BMPR-II) phosphorylates type I receptors, and this 
complex, in turn, phosphorylates the Smads 1, 5 and 8. These phosphorilated Smads form a heteromeric 
complex with Smad4 that translocates into the nucleus and induces the expression of hepcidin. Adapted 
from Anderson and Frazer, 2006. 
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The HJV gene has 4.2 kb and when transcribed produces one transcript 
corresponding to the functional protein (transcript 1) and four other transcripts resulting 
from alternative splicing (Figure 3) [20]. Transcript 1 contains all exons and encodes for 
a protein with 426 amino acid, which has a signal peptide, tri-amino acid motif (RGD), 
partial von Willebrandt factor (vWf) and transmembrane motif characteristic of a 
glycosylphosphatidylinositol (GPI) anchor [14]. Transcript 2 encodes for a protein with 
314 amino acids while the remaining transcripts (3, 4 and 5) encodes for a 200 amino 
acids peptide [14]. Translation of transcript 3 could potentially begin in the same start 
codon as in transcript 1, but would originate a downstream frameshift leading to an 
earlier stop codon creating a truncated protein. Nonetheless, according to figure 3, 
translation of transcript 3 would start in the same codon as variants 4 and 5 producing 
the same protein. However, transcript 3 is not defined in the transcriptome database, 
despite being initially described by Papanikolaou and colleagues (2004).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Representation of human HJV transcripts and the ORF structure. Coding regions are 
represented as black boxes, non-coding regions are represented as white boxes and introns are represented 
as lines. Below is represented the ORF structure correspondent to the protein motifs: SP-signal peptide, 
RGD-repulsive guidance domain, vWf-von Willebrand factor D and TM-transmembrane domain. 
Adapted from Papanikolau et al, 2004. 
 
HJV mRNA expression occurs in the liver, skeletal and cardiac muscle [14][21]. 
HJV can be found in two forms: soluble and membrane [20]. Soluble HJV lacks GPI 
anchor and is produced in the heart and skeletal muscle (where hepcidin is not 
produced) [19][20]. This soluble HJV has been described as a negative modulator of 
hepcidin synthesis through membrane HJV competition [22]. Membrane HJV, which 
contains the GPI anchor, is produced in the liver and is involved in the regulation of 
hepcidin as mentioned above [20].  
6 
 
Not only the alternative splicing can influence the gene expression, the 5’ leader 
sequence of a mRNA can also alter the efficiency of protein production [23]. Some 
mRNAs have in their 5’ leader sequence, cis-acting elements that can regulate gene 
expression. For example, upstream AUGs (uAUGs) that when associated to an in frame 
stop codon create upstream open reading frames (uORFs) [24][25]. These uORFs can 
be recognized by the ribosome decreasing the protein production codified by the main 
ORF [24][25]. The HJV 5’ leader sequence of the transcript 1 has two uAUGs in the 
first exon. The in frame stop codon is common for both uORFs and it is located in the 
second exon, as well as the main AUG codon. How uORFs can affect translation is 
exposed in the next chapter.  
 
1.4. Regulation of translation by uORFs  
In eukaryotes, post-transcriptional pathways such as mRNA processing, export, 
translation and turnover, provide the means to regulate gene expression at many levels. 
Translation, the process of protein synthesis from an mRNA template, can be divided 
into three phases - initiation, elongation and termination. Most translational regulation is 
exerted at the initiation step, where the AUG codon is identified and decoded [26][27]. 
However, accumulating evidence has revealed that when translation is inhibited by cell 
stress, alternative mechanisms of translation initiation act to maintain the synthesis of 
certain proteins required either for the stress response or to aid recovery from the stress 
stimulus. These pathways are evolutionarily conserved and have been shown to 
dramatically impact translation in organisms as diverse as yeast and humans. In many 
cases, features in the 5’ leader sequences of these mRNAs are important for 
translational control. These include small structural elements that interact with trans-
acting factors, internal ribosome entry sites (IRES) and uORFs [26][27].  
The translation initiation in eukaryotes is a cap-dependent scanning mechanism 
performed by the ribosome [27][28]. To initiate translation, the eukaryotic initiation 
factor 4F (eIF4F) complex needs to be assembled. This complex is composed by the 
cap-binding protein eIF4E, as well as eIF4A and eIF4G [29]. Once the eIF4F complex 
is created, the 43S pre-initiation complex is recruited to scan the mRNA in a 5’-3’ 
direction until it encounters an AUG [24][30]. The 43S pre-initiation complex 
comprises the 40S ribosome subunit, the initiation factors 1, 1A, 3 and 5, and the eIF2-
GTP-Met-tRNAi ternary complex [24]. Once the 43S pre-initiation complex recognizes 
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the initiation codon, the 60S subunit is assembled by the irreversible hydrolysis of GTP 
in the eIF2-GTP-Met-tRNAi complex, forming the 80S ribosome, and elongation starts 
[24] [27].  
The translational efficiency of eukaryotic mRNAs depends on the nucleotide 
sequence flanking the start codon (start codon context) and on the structural features of 
the mRNA 5’ leader sequence such as the 5’ leader sequence length, the secondary 
structure and the presence of uAUGs [23][31]. These uAUGs when associated to an in 
frame stop codon, originate an uORF, that precedes the main ORF which encodes the 
functional protein [24][25]. Regarding to the uORF stop codon position, three different 
arrangements may arise: (1) the stop codon is located in the 5’ leader sequence and the 
uORF is autonomous, (2) the stop codon is out of frame but within the main ORF and 
thus the uORF overlaps the downstream main ORF, (3) the stop codon is in frame with 
the main ORF, and thus will be synthesized a protein isoform with an extended N-
terminal region [32].  
It is important to notice that uAUGs and uORFs are present in several taxonomic 
classes [31]. Evolutionary studies actually revealed that uORFs are targeted for 
selection more than uAUGs, suggesting that at least some of them are involved in the 
translational control of mRNAs [31][33]. In the human species, uORFs are quite 
common in some gene classes, such as oncogenes and genes involved in the cellular 
growth control and differentiation [34][35].   
As mentioned above, the context of the start codon determines whether it is 
recognized or not by the translational machinery [31]. According to the Kozak’s 
scanning model, the ideal context in higher eukaryotes at the start AUG codon is 
GCCRCCAUGG, where R can be G or A [28]. The most critical sites near the start 
codon are the positions -3 and +4 [36][37]. Contexts AnnAUGn and GnnAUGG are 
considered to be strong enough to be recognized by the majority of scanning ribosomes 
[32]. When mutations weaken the context of an uAUG codon, being often less 
recognized by ribosomes, it enhances the translation of the downstream ORF [38]. On 
the other hand, when mutations strengthen a weak uAUG codon, downstream 
translation is reduced [38].   
Several uAUG codons do not have the optimal sequence, lacking both R in 
position -3 and G in position +4, but some ribosomes still initiate translation at the 
uAUG [24]. Besides this recognition, the ribosome might ignore the first AUG, scan 
past it and recognize the downstream AUG by the leaky scanning mechanism [35]. This 
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mechanism depends not only on the AUG context, but also on the proximity to the cap, 
the length of 5’ leader sequence and the secondary structures of the transcript [34]. So, 
the translation frequency of the main ORF depends on uAUG recognition [34]. 
Even after the translation of the uORF, the main ORF can still be translated due 
to reinitiation [25][34]. Translation reinitiation occurs when the 40S subunit of the 
ribosome remains associated to the mRNA even after the uORF translation terminates, 
so it resumes scanning and reinitiates further downstream [25][34]. For the next AUG 
codon to be recognized, the 40S subunit has to reload the eIF2-GTP-Met-tRNAi [24]. In 
this matter, the efficiency of the reinitiation depends on the length of intercistronic 
region and the secondary structures existent in the transcript [24][25][34]. Regarding 
uORF length, the reinitiation tends to be less efficient after the translation of a longer 
uORF [25]. This is due to the fact that the ribosome need to retain several associated 
initiation factors to be able to reinitiate [25]. Consequently, ribosomes in longer uORFs, 
or with low translational rates, will be less prone to reinitiate. In contrast, ribosomes in 
smaller uORFs will retain more associated initiation factors to reinitiate translation at a 
downstream AUG [25].  
During translation of an uORF, ribosomes may stall through a mechanism 
involving the uORF encoded peptide, at either the elongation or the termination steps 
[25]. This ribosomal blockade might pose an obstacle to the scanning ribosome and 
thereby reduce the number of ribosomes that, by leaky scanning or reinitiation, gain 
access to the main AUG codon [34][38]. The so far characterized uORFs that act trough 
this mechanism do not share any recognizable consensus sequence, suggesting that the 
different peptides interact with distinct sites in the translational machinery [34].  
The presence of uORFs can also affect mRNA stability, triggering cell 
surveillance mechanisms such as nonsense-mediated mRNA decay (NMD) [24]. NMD 
is a pathway that targets mRNAs harbouring a premature translation termination codon 
(PTC) to rapid decay [39]. This pathway is important to degrade PTC-containing 
mRNAs that could produce truncated proteins, leading to potentially deleterious 
dominant-negative or gain-of-function effects [40]. Production of PTC-containing 
mRNAs could be caused by random nonsense and frameshift DNA mutations, somatic 
rearrangements in the DNA, aberrant alternative splicing or utilization of alternative 
AUG initiation sites [39][40][41]. The stop codon of an uORF can be recognized by the 
ribosome as a PTC, and thus triggering the NMD machinery. However, this is not 
imperative, because not all mRNAs that contain uORFs are physiological targets of 
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NMD [42]. In this manner, the positioning of PTCs relatively to the initiation codon 
influences the mRNA resistance to NMD, since transcripts that bear PTCs closer to the 
AUG escape NMD [43]. Indeed, the beta-globin transcripts that bear PTCs on the codon 
15 or less evade NMD due to an AUG-proximity effect, thanks to the interaction 
between eukaryotic release factor 3 (eRF3) and cytoplasmic poly(A)-binding protein 1 
(PABPC1) [44]. In contrast, the beta-globin transcripts with PTCs located further from 
the AUG such as at codon 39 does not benefit from the protection of this interaction, 
been targeted to NMD [44]. In the HJV 5’ leader sequence are two uAUGs with the 
same in frame stop codon, which forms two uORFs, the first one (uORF1) has 28 
codons and the second one (uORF2) 19 codons. Therefore, the HJV transcript is a 
candidate to be an NMD target, since the termination codon is located in a position not 
favourable for the protection interaction between eRF3 and PABPC1.  
For all the reasons mentioned above, the uAUGs may be considered as 
regulatory elements that maintain the low constitutive level of expression of proteins 
that need to be closely regulated [31]. 
Regarding Kozak’s scanning model, both HJV uAUG1 (GAATCAUGG) and 
main AUG (TAGGTAUGG) have a good context, in contrast to uAUG2 
(GAGTAAUGT) that despite having an adequate base in position -3 lacks the suitable 
base in the position +4. Thus, since uAUG1 has an optimal context, it can be 
theoretically recognized by the ribosome, during the scanning process, as the first AUG, 
translating the uORF1. This event establishes a barrier that prevents ribosome accessing 
to the main ORF.  
The intercistronic region of the HJV transcript has 52 nucleotides which may 
allow the reinitiation mechanism. As mentioned before, this distance is essential for the 
initiation factors to remain attached to the ribosome and to reacquire the ternary 
complex.  
The knowledge of the mechanisms involved in the human HJV gene expression 
is extremely important to identify potential targets for therapeutic intervention in 
diseases associated with iron metabolism. Therefore, in this thesis, we aimed to 
investigate the role of both uORFs in the regulation of the human HJV protein 
expression. With this propose, we addressed the following questions: 
1. What is the effect of both uORFs on the translational regulation of HJV 
expression? 
2. What are the mechanisms by which the HJV uORFs regulate translation? 
10 
 
2. Methods 
 
2.1. Plasmid constructs 
The native human HJV mRNA 5’ leader sequence (harboring both uORFs) was 
cloned into the HindIII/XbaI site of the pGL2-enhancer expression vector (Promega), in 
a way to be fused to the firefly Luciferase cistron (firefly luc). This plasmid also carries 
the human cytomegalovirus (hCMV) promoter (Figure 4).  
 
hCMV promotor
uAUG1 uAUG2 UAG AUG
LUCIFERASE
uORF1
uORF2
5’ Leader region of the HJV mRNA
XbaI
 
Figure 4. Representation of the pGL2-enhancer vector where the DNA fragment corresponding to 
the human HJV 5’ leader sequence was cloned in the HindIII/XbaI cloning site. 
 
Then, we obtained, by site-directed mutagenesis, several mutant constructs in 
which different mutations were introduced into the human HJV mRNA 5’ leader 
sequence. Site-direct mutagenesis was performed by using PfuTurbo® DNA 
Polymerase (Invitrogen) as instructed by the manufacturer, mutagenic primers as 
indicated in the annexed Table I and the plasmid with the wild-type HJV 5’ leader 
sequence as DNA template. PCR cycling was as follows: after initial denaturation for 
10min at 95ºC, PCR cycling parameters were 95ºC (1min), 55ºC (1min), and 72º C 
(16min), for a total of 11 cycles with a final extension at 72ºC (10min). Following DpnI 
(Fermentas) restriction digestion of the template, DH5α bacteria were transformed with 
the mutagenesis reaction, and transformants were selected on luria-bertani (LB) 
agar/ampicillin plates. The corresponding plasmid DNAs were purified from overnight 
cultures of single colonies with Jetquick Plasmid Purification Spin Kit (Genomed) 
following the manufacturer instructions. Confirmation of the correct cloned sequences 
containing the relevant mutation was carried out by automatic sequencing. 
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The obtained constructs were: 
1. “5’ Leader OK” – native 5’ leader sequence (figure 5A). 
2. “Only uORF1” – only uORF1 present due to mutation of uAUG2 (ATG 
to TTG) (figure 5A). 
3. “Only uORF2” – only uORF2 present through mutation of uAUG1 (ATG 
to TTG) (figure 5A). 
4. “uORFs KO” – inactivation of both uORFs by mutation of both uAUGs 
(ATG to TTG) (figure 5A). 
5. “Better Kozak both uAUGs” – both uAUGs sequence contexts improved 
to optimal Kozak context, by mutagenesis (uAUG1: GAATCATGG to 
GAACCATGG) (uAUG2: GAGTAATGT to GAGCCATGG) (figure 
6A). 
6. “Better Kozak only uAUG1” – uAUG1 sequence context improved to 
optimal context (GAATCATGG to GAACCATGG) and uORF2 
inactivated by mutagenesis (ATG to TTG) (figure 6A). 
7.  “Better Kozak only uAUG2” – uAUG2 context improved to optimal 
context (GAGTAATGT to GAGCCATGG) and uORF1 inactivated by 
mutagenesis (ATG to TTG) (figure 6A). 
8. “Overlap both uORFs” – both uORFs overlap with the main ORF by 
mutation of the uORFs stop codon (TAG to AAG) (figure 7A). 
9. “Overlap only uORF1” – only uORF1 overlaps with the main ORF by 
mutation of the uORFs stop codon (TAG to AAG) and mutation of the 
uAUG2 (ATG to TTG) (figure 7A). 
10. “Overlap only uORF2” – only uORF2 overlaps with the main ORF by 
mutation of the uORFs stop codon (TAG to AAG) and mutation of the 
uAUG1 (ATG to TTG) (figure 7A). 
11. “Sequence Alteration both uORFs” – both uORFs coding sequences 
change through two frameshifts. First frameshift: deletion of a T after the 
uAUG1 (ATGGCTG to ATGGCG), insertion of a C before the uAUG2 
(GATAGC to GATACGC). Second frameshift: deletion of a T after the 
uAUG2 (ATGTTT to ATGTT) and insertion of a C before the stop 
codon (TAGGTAG to TACGGTAG) (figure 8A). 
12. “Sequence Alteration only uORF1” – uORF1 coding sequence changes 
through two frameshifts. First frameshift: deletion of a T after the 
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uAUG1 (ATGGCTG to ATGGCG), insertion of a C before the uAUG2 
(GATAGC to GATACGC). Second frameshift: deletion of a T after the 
uAUG2 (ATGTTT to ATGTT) and insertion of a C before the stop 
codon (TAGGTAG to TACGGTAG). The uORF2 was inactivated by 
mutagenesis (ATG to TTG) (figure 8A). 
13. “Sequence Alteration only uORF2” – uORF2 coding sequence changes 
through one frameshift: deletion of a T after the uAUG2 (ATGTTT to 
ATGTT) and insertion of a C before the stop codon (TAGGTAG to 
TACGGTAG). The uORF1 was inactivated by mutagenesis (ATG to 
TTG) (figure 8A). 
14. “Sequence Alteration of both uORFs mut stop” – mutation of the uORFs 
stop codon (TAG to AAG), in the “Sequence Alteration both uORFs” 
construct (figure 9A). 
15. “Sequence Alteration of only uORF1 mut stop” – mutation of the uORF1 
stop codon (TAG to AAG) in the “Sequence Alteration only uORF1” 
construct (figure 9A). 
16. “Sequence Alteration of only uORF2 mut stop” – mutation of the uORF2 
stop codon (TAG to AAG) in the “Sequence Alteration only uORF2” 
construct (figure 9A). 
17. “Individual codon change of the amino acid 3” – the third codon of the 
“Only uORF1” construct is changed without altering the encoded amino 
acid (GGA to GGG) (Table 2).  
18.  “Individual codon change of the amino acid 4” – the forth codon of the 
“Only uORF1” construct is changed without altering the encoded amino 
acid (GAA to GAG) (Table 2). 
19. “Individual codon change of the amino acid 5” – the fifth codon of the 
“Only uORF1” construct is changed without altering the encoded amino 
acid (TTG to CTT) (Table 2). 
20. “Individual codon change of the amino acid 6” – the sixth codon of the 
“Only uORF1” construct is changed without altering the encoded amino 
acid (GAT to GAC) (Table 2). 
21. “Individual codon change of the amino acid 7” – the seventh codon of the 
“Only uORF1” construct is changed without altering the encoded amino 
acid (AGC to TCC) (Table 2). 
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22. “Individual amino acid change to Alanine 3” – the third codon of the 
“Only uORF1” construct is changed from Glycine to Alanine (GGA to 
GCA) (Table 3).  
23. “Individual amino acid change to Alanine 4” – the forth codon of the 
“Only uORF1” construct is changed from Glutamic acid to Alanine 
(GAA to GCT) (Table 3). 
24. “Individual amino acid change to Alanine 5” – the fifth codon of the 
“Only uORF1” construct is changed from Leucine to Alanine (TTG to 
GCA) (Table 3). 
25. “Individual amino acid change to Alanine 6” – the sixth codon of the 
“Only uORF1” construct is changed from Aspartic acid to Alanine (GAT 
to GCT) (Table 3). 
26. “Individual amino acid change to Alanine 7” – the seventh codon of the 
“Only uORF1” construct is changed from Serine to Alanine (AGC to 
GCT) (Table 3). 
27. “Individual amino acid change to the same type of amino acid 4” – the 
forth codon of the “Only uORF1” construct is changed from Glutamic 
acid to Aspartic acid (GAA to GAC) (Table 4). 
28. “Individual amino acid change to the same type of amino acid 6” – the 
sixth codon of the “Only uORF1” construct is changed from Aspartic 
acid to Glutamic acid (GAT to GAA) (Table 4). 
29. “Individual amino acid change to the same type of amino acid 7” – the 
seventh codon of the “Only uORF1” construct is changed from Serine to 
Threonine (AGC to ACC) (Table 4). 
30. “Hybrid 1” – the “Only uORF1” construct is frameshifted between the 
uAUG1 and uAUG2 by a deletion of a T after the uAUG1 (ATGGCTG 
to ATGGCG) and an insertion of a C before the uAUG2 (GATAGC to 
GATACGC). The region between uAUG2 and the stop codon is 
maintained (figure 12A).  
31. “Hybrid 2” – the “Only uORF1” construct is frameshifted between the 
uAUG2 and the stop codon by a deletion of a T after the uAUG2 
(ATGTTT to ATGTT) and an insertion of a C before the stop codon 
(TAGGTAG to TACGGTAG). The region between the uAUG1 and the 
uAUG2 is maintained (figure 12A).  
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32. “Consecutive sequence alteration 2” – the uORF2 codon 2 of the “Only 
uORF2” construct is mutated in order to be the same as that one of the 
“Sequence alteration only uORF2” construct (Table 5).   
33. “Consecutive sequence alteration 3” – the uORF2 codon 3 of the 
previous “Consecutive sequence alteration 2” construct is mutated in 
order to be the same as that one of the “Sequence alteration only uORF2” 
construct (Table 5).  
34. “Consecutive sequence alteration 4” – the uORF2 codon 4 of the 
previous “Consecutive sequence alteration 3” construct is mutated in 
order to be the same as that one of the “Sequence alteration only uORF2” 
construct (Table 5).  
35. “Consecutive sequence alteration 5” – the uORF2 codon 5 of the 
previous “Consecutive sequence alteration 4” construct is mutated in 
order to be the same as that one of the “Sequence alteration only uORF2” 
construct (Table 5).  
36. “Consecutive sequence alteration 6” – the uORF2 codon 6 of the 
previous “Consecutive sequence alteration 5” construct is mutated in 
order to be the same as that one of the “Sequence alteration only uORF2” 
construct (Table 5). 
37. “Consecutive sequence alteration 7” – the uORF2 codon 7 of the 
previous “Consecutive sequence alteration 6” construct is mutated in 
order to be the same as that one of the “Sequence alteration only uORF2” 
construct (Table 5). 
38. “Consecutive sequence alteration 8” – the uORF2 codon 8 of the 
previous “Consecutive sequence alteration 7” construct is mutated in 
order to be the same as that one of the “Sequence alteration only uORF2” 
construct (Table 5). 
39. “Consecutive sequence alteration 9” – the uORF2 codon 9 of the 
previous “Consecutive sequence alteration 8” construct is mutated in 
order to be the same as that one of the “Sequence alteration only uORF2” 
construct (Table 5). 
40. “Consecutive sequence alteration 10” – the uORF2 codon 10 of the 
previous “Consecutive sequence alteration 9” construct is mutated in 
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order to be the same as that one of the “Sequence alteration only uORF2” 
construct (Table 5). 
41. “Consecutive sequence alteration 11” – the uORF2 codon 11 of the 
previous “Consecutive sequence alteration 10” construct is mutated in 
order to be the same as that one of the “Sequence alteration only uORF2” 
construct (Table 5). 
42. “Consecutive sequence alteration 12” – the uORF2 codon 12 of the 
previous “Consecutive sequence alteration 11” construct is mutated in 
order to be the same as that one of the “Sequence alteration only uORF2” 
construct (Table 5). 
43. “Consecutive sequence alteration 13” – the uORF2 codon 13 of the 
previous “Consecutive sequence alteration 12” construct is mutated in 
order to be the same as that one of the “Sequence alteration only uORF2” 
construct (Table 5). 
44. “Consecutive sequence alteration 14” – the uORF2 codon 14 of the 
previous “Consecutive sequence alteration 13” construct is mutated in 
order to be the same as that one of the “Sequence alteration only uORF2” 
construct (Table 5). 
45. “Consecutive sequence alteration 15” – the uORF2 codon 15 of the 
previous “Consecutive sequence alteration 14” construct is mutated in 
order to be the same as that one of the “Sequence alteration only uORF2” 
construct (Table 5). 
46. “Consecutive sequence alteration 16” – the uORF2 codon 16 of the 
previous “Consecutive sequence alteration 15” construct is mutated in 
order to be the same as that one of the “Sequence alteration only uORF2” 
construct (Table 5). 
 
2.2. Cell culture 
HepG2 cells (human hepatocellular carcinoma cell line) was a courtesy of 
Laboratório de Hemoglobinopatias of the Instituto Nacional de Saúde Dr. Ricardo 
Jorge. This cells were maintained in T80 tissue culture flask (Sarstedt) with 15mL of 
Roswell Park Memorial Institute (RPMI + Glutamax-I; Gibco) supplemented with 10% 
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fetal bovine serum (FBS) incubated at 37°C with an atmosphere of 4% CO2. The 
passage of the cells was carried out every 3 to 4 days for dilutions ranging from 1:3 to 
1:5. Since they are adherent cells, their passage was made by removing the culture 
medium and adding 1mL of trypsin for approximately 2 minutes (min) at 37°C in order 
to break the bonds with the surface of the flask. The cells were resuspended in RPMI + 
GlutaMAX
TM
-I and changed to another T80 tissue culture flask, previously prepared 
with 15mL of medium supplemented with 10% FBS. 
 HeLa cells (human cervical cancer cell line) were cultured in T80 tissue culture 
flasks with 15mL of Dulbecco’s modified Eagle medium (DMEM + GlutaMAXTM-I; 
Gibco) supplemented with 10% FBS and incubated at 37°C with an atmosphere of 4% 
CO2. The passage of the cells was carried out every 3 to 4 days by dilutions from 1:2 to 
1:5 using the same process above mentioned but using the DMEM + GlutaMAX
TM–I 
medium.  
These cells were also frozen in order to maintain a stock of each cell line. For 
this purpose, cells were incubated in T80 tissue culture flasks until they reached a 
confluence of approximately 90%. After trypsinised, cells were resuspended in 5mL of 
the respective culture medium and centrifuged for 5min at 1200rpm. The culture 
medium was removed and 2mL of freezing solution (90% FBS, 10% dimethylsulfoxide) 
were added to the cell pellet. The cells were gently resuspended in this solution and 
divided in two CryoPure tubes (Sarstedt) that were submitted to a gradual freezing until 
-80ºC. Then, they were stocked at liquid nitrogen.  
 
2.3. Transfection of cultured cells  
The aforementioned cell lines were seeded in six-well plates (Sarstedt) using a 
number of cells necessary to obtain in the next day approximately 70% to 90% of 
confluence. For each well, we used 2mL of the medium supplemented with 10% FBS. 
After 24 hours (h) of incubation at 37°C in a 4% CO2 atmosphere the cell lines were 
transfected. HeLa and HepG2 cell lines were co-transfected with 500ng of the 
expression vector pRL-TK (Promega) and 1500ng of the expression vector in study, in 
order to have a ratio of two vectors of 1:3. To perform the transfection, the plasmids 
were diluted in 125μL of Opti-MEM medium (Gibco) being mixed gently. In parallel, a 
dilution of 4μL lipofectaminaTM 2000 (Invitrogen) in 125μL of Opti-MEM was 
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performed, which was incubated for 5min at room temperature. After this period, each 
expression vector preparation was gently mixed and incubated for 20min at room 
temperature. Finally, this mixture was distributed per well of culture plate, whose 
medium had been previously replaced. The six-well plates were incubated for 20h and 
24h at 37°C for HeLa and HepG2, respectively, in an atmosphere of 4% CO2.  
 
2.4. Luminometry assay  
This assay quantifies the production of Luciferase protein by measuring their 
enzymatic activity in the presence of a substrate, a derivative from luminol, which when 
metabolized emits photons that can be detected using a luminometer. The Luciferase 
activity was determined using the Dual Luciferase Reporter Assay System (Promega) 
and a luminometer Lucy 2 (Anthos). Twenty hours after HeLa cells transfection and 24h 
after for HepG2 cells transfection, the active cell lysis for protein and RNA extraction 
was carried out. The active cell lysis was performed with 40μL, of 1x passive lysis 
buffer concentrate (PLB, Promega), per well, in HeLa cells. For HepG2 cells, the active 
cell lysis was performed with 35µl of PLB buffer. The lysates were quickly frozen at 
 -80°C, and then thawed at 37°C and centrifuged at 16000rpm for 30 seconds (sec). The 
subsequent analysis of Luciferase activity was performed according to the instruction 
manual of Promega. The assay consists of sequential luminescence measuring of the 
firefly Luciferase and Renilla Luciferase activity, in the same reaction. This is possible 
because the two enzymes have different structures and substratum requests. After the 
Luciferase substratum addition, the luminescence activity is measured by substratum 
degradation. Afterwards, the Renilla Luciferase substratum is added, in order to inhibit 
the firefly Luciferase activity, and the luminescence activity of the Renilla Luciferase is 
measured. The Renilla Luciferase activity acts as an internal control for the firefly 
Luciferase activity measurement. 
 
2.5. RNA extraction 
The transfected HeLa and HepG2 cell lines above mentioned were used for total 
RNA extraction, using the RNA extraction kit NucleoSpin RNA II (Macherey-Nagel) 
according to the manual provided by the manufacturer. 
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2.6. RT-qPCR  
The extracted RNA was used as template to synthesize cDNA using the kit 
SuperScriptTM II Reverse Transcriptase (Invitrogen). The procedure was performed 
according to the stipulations of the manual, using 1µg of total RNA. The reverse 
transcription quantitative PCR reaction (RT-qPCR) was performed using 
oligonucleotide primers, designed specifically for the Renilla and Luciferase genes 
(Annex, Table I), obtaining fragments of 108 base pairs (bp) and 150bp, respectively. 
This reaction also contained DNA double-chain intercalating SYBR Green PCR master 
mix (Applied Biosystems) and nucleotides, including dUTP. The PCR program 
consisted of an initial denaturation step at 95°C for 10min, followed by forty cycles 
including a denaturation step at 95°C for 15sec and an extension step at 61°C for 30sec. 
The reaction was analysed using the real-time PCR ABI PRISM 7000 instrument 
(Applied Biosystems). In order to quantify the cDNA in study, several dilutions were 
performed. For HeLa cells RNA, an initial dilution of 1:50 for all samples was required. 
To determine the primers efficiency, series of dilutions were made in order to obtain a 
calibration curve. The cDNA quantification was performed by the ΔΔCT method. 
 
2.7. Statistical analysis 
Results are expressed as mean ± standard deviation. Student’s t test was used for 
estimation of statistical significance (unpaired, two tails). Significance for statistical 
analysis was defined as a p< 0.05 [45]. 
 
 
 
 
 
 
 
  
 
 
19 
 
3. Results 
 
3.1. The human HJV uORFs inhibit translation of the downstream main 
ORF  
  The human HJV transcript (NM_213653) presents a 5’ leader sequence with 325 
nucleotides. Within this region, there are two AUGs located upstream of the main ORF, 
which in turn encodes for the functional HJV protein. These two uAUGs share the same 
in-frame stop codon, also present in the 5’ leader sequence, and thus create two 
overlapped uORFs. The first uORF (uORF1) has 28 codons and the second one 
(uORF2) has 19 codons, and they both dist from the main AUG by 52 nucleotides, 
which corresponds to the intercistronic region (Figure 4).  
In order to assess the function of these uORFs in the HJV protein expression 
regulation, the DNA fragment with 325 nucleotides corresponding to the human HJV 5’ 
leader mRNA sequence, plus the AUG of HJV main ORF, was cloned upstream to the 
firefly Luciferase gene present in the pGL2 plasmid (see Methods; Figure 4). The 
cloning strategy was planned in the way to get the native HJV main AUG codon 
matching with the firefly Luciferase AUG, mimicking the physiological conditions of 
the human HJV mRNA (“5’ Leader OK” construct; Figure 5A). Additionally, using this 
“5’ Leader OK” construct as template, we obtained, by site-directed mutagenesis, three 
other constructs: one carrying a mutation (AUG to UUG) in the second uAUG (“Only 
uORF1” construct; Figure 5A), other carrying the AUG to UUG mutation in the first 
uAUG (“Only uORF2” construct; Figure 5A), and another carrying the same mutation 
(AUG to UUG) at both uAUGs (“uORFs KO” construct; Figure 5A). The last construct 
represents the HJV 5’ leader sequence without any uORF, which might reveal the 
maximum capacity of the HJV mRNA translation. Together, these clones allowed us to 
analyze the effect of each one of the uORFs individually, or the effect of both uORFs, 
on the human HJV translational efficiency. For that, the four constructs were transiently 
transfected in HeLa and HepG2 cells. Then, cells were lysed and protein and mRNA 
was isolated. Protein expression levels of each construct were quantified by 
luminometry assays and the mRNA levels quantified by RT-qPCR. Results were 
normalized to those of the normal control, the so called “5’ Leader OK” construct 
(Figure 5B and C). 
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Figure 5. The human HJV uORFs decrease the translation efficiency of the downstream ORF. (A) 
Representation of the constructs transiently expressed in HeLa and HepG2 cells. “5´ Leader OK”: Native human 
HJV 5’ leader mRNA sequence that includes the two uORFs and intercistronic sequence linked to the main ORF 
Luciferase. “Only uORF1”: 5’ Leader mRNA sequence with only the uORF1 due to mutation of uAUG2 (AUG to 
UUG). “Only uORF2”: 5’ Leader mRNA sequence with only the uORF2 due to mutation of uAUG1 (AUG to 
UUG). “uORFs KO”: 5’ Leader mRNA sequence without uORFs due to mutation of both uAUGs. AUG=initiation 
codon; UAG=stop codon; orange brackets=uORFs; yellow box=Luciferase mRNA sequence. (B) Relative Luciferase 
activity expressed in HeLa and HepG2 cells for each of the constructs represented in (A). Data correspond to the ratio 
of the enzymatic activity of firefly Luciferase relatively to the Renilla Luciferase and normalized for the amount of 
protein encoded by the “5' Leader OK” construct. Statistical analysis was performed using Student’s t test (unpaired, 
two tails); *statistically significant. (C) Relative levels of mRNA in HeLa cells expressing each one of the constructs 
represented in (A). Data correspond to the ratio of the mRNA levels of firefly Luciferase cistron relatively to that of 
Renilla Luciferase and normalized for the amount of mRNA expressed by the “5’ Leader OK” construct. 
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The obtained results have shown that the “Only uORF1” construct has higher 
levels of protein expression when compared to those of the “5’ Leader OK” construct in 
HeLa cells (1.6-fold increase; p=0,0227), but not in HepG2 cells (p=0,0856) (Figure 
5B). In addition, “Only uORF2” construct has significantly higher luciferase activity 
than the “5’ Leader OK” construct, with about a 3-fold increase, in both cell types 
(HepG2 cells: p=8,053x10
-6
; HeLa cells: p=0,0064). On the other hand, protein levels 
expressed from “uORFs KO” construct are much higher than those obtained from the 
normal control, showing a 7-fold increase in translational efficiency in HepG2 cells 
(p=0,0004) and a 5-fold increase in HeLa cells (p=0,0043) (Figure 5B), which is in 
accordance with what was expected as this construct does not carry any uORF. Of note, 
mRNA levels for each construct are comparable (Figure 5C), meaning that changes in 
protein levels (Figure 5B) are due to differences in translational rate. 
Taken together, these results reveal that uORF1 and uORF2 are both functional 
in the human HJV transcript, preventing the main ORF to be fully translated. However, 
the uORF1 is a stronger repressor of translation than the uORF2. Furthermore, we 
observe a cumulative effect in repression when both uORFs are functional. This set of 
data demonstrates that the human HJV uORFs serve as cis-acting regulatory elements 
for HJV protein expression. 
 
3.2. The HJV main ORF is recognized by translation reinitiation  
Knowing that the human HJV uORFs repress translation of the downstream HJV 
coding region, we next aimed to further understand the mechanism by which the HJV 
main ORF is recognized by the ribosome. For that, we first considered the reinitiation 
mechanism, which indicates that following translation of the inhibitory uORFs, the 
ribosomes might, at least some times, resume scanning and reinitiate translation at the 
HJV coding region [25][34]. To test for the occurrence of this mechanism, we mutated 
the AUG codon sequence context of both HJV uORFs to obtain an optimal Kozak 
sequence context (“Better Kozak both uAUGs” construct; Figure 6A), ensuring the 
maximum ribosome reading of the uORFs and impeding the leaky scanning to occur. 
Additionally, each of the uAUGs sequence context was improved individually while the 
other uORF was inactivated by mutation of the corresponding AUG (AUG to UUG) 
(“Better Kozak only uAUG1” and “Better Kozak only uAUG2” constructs; Figure 6A). 
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After transient transfection of HeLa and HepG2 cells with each one of these constructs, 
cells were lysed and protein and total RNA were isolated. Luciferase activity from each 
construct was analyzed as before as well as the mRNA levels. Results were normalized 
to the normal control (the “5’ Leader OK” construct) and compared with those of the 
corresponding original construct (Figure 6B). 
Results show that the “Better Kozak both uAUGs” construct is expressed at the 
same protein levels as the “5’ Leader OK” construct, in both HeLa (p=0,8882) and 
HepG2 cells (p=0,1225) (Figure 6B). Also, the constructs with only one uAUG in an 
optimal Kozak sequence context (“Better Kozak only uAUG1” and “Better Kozak only 
uAUG2” constructs; Figure 6A) were expressed at protein levels comparable to those of 
the “Only uORF1” and “Only uORF2” constructs, in both HeLa (p= 0,2014; p= 0,3502) 
and HepG2 cells (p=0,3584; p=0,3816), respectively (Figure 6B). As mRNA levels 
expressed from each one of the constructs are similar (Figure 6C), alterations in protein 
levels occur at the translation level. Thus, we can conclude that increasing the uAUG 
sequence context for a better Kozak sequence context, in each one of the uAUGs, does 
not affect protein levels of the downstream main ORF, meaning that the native uAUGs 
are in a good sequence context to be recognized by the ribosome as initiators. Indeed, 
the translation rate tends to remain unaltered when we compare results from the set of 
the “Better Kozak” constructs with those from the native AUG context sequence 
constructs (Figure 6B). These data indicate that HJV uAUGs, or at least uAUG1, might 
be recognized by the ribosome with high frequency, being the HJV uORFs (at least 
uORF1) efficiently translated. Thus, this data prompt us to suggest that translation of 
the downstream main ORF might occur mainly by reinitiation.   
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Figure 6. Preventing leaky scanning by improving the Kozak sequence context of the uAUGs does not affect 
the Luciferase protein expression levels. (A) Representation of the “Better Kozak” constructs transiently expressed 
in HeLa and HepG2 cells. “Better Kozak both uAUGs”: HJV 5’ Leader mRNA sequence with both uAUGs 
contexts improved for an optimal sequence context. “Better Kozak only uAUG1”: HJV 5’ Leader mRNA sequence 
with only the uAUG1 with optimal context. The uORF2 is inactivated due to mutation (AUG to UUG) of uAUG2. 
“Better Kozak only uAUG2”: HJV 5’ Leader mRNA sequence with only the uAUG2 with optimal context. The 
uORF1 is inactivated due to mutation (AUG to UUG) of uAUG1. The native uAUG sequence context for each uORF 
is under each construct with black letters, the new context is also indicated (the changed nucleotides are represented 
with red letters). AUG=initiation codon; UAG=stop codon; orange brackets=uORFs; yellow box=Luciferase mRNA 
sequence. (B) Relative Luciferase activity expressed in HeLa and HepG2 cells for each of the constructs represented 
as in (A). Data correspond to the ratio of the enzymatic activity of firefly Luciferase relatively to the Renilla 
Luciferase and normalized for the amount of protein encoded by the “5' Leader OK” construct. Statistical analysis 
was performed using Student’s t test (unpaired, two tails). (C) Relative mRNA levels from each of the constructs, as 
indicated below the graph, expressed in HeLa cells. Data correspond to the ratio of the mRNA levels of firefly 
Luciferase relatively to Renilla Luciferase and normalized for the amount of mRNA expressed by the “5' Leader OK” 
construct.  
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3.3. The HJV transcript supports low leaky scanning 
We next addressed whether the HJV main ORF can be translated, at least some 
times, by the leaky scanning mechanism. In this mechanism, the scanning ribosome 
would bypass and scan through the inhibitory uORFs and could initiate translation at the 
downstream main AUG [35]. To test for the occurrence of this mechanism, we mutated 
the stop codon of the HJV uORFs to a sense codon (UAG to AAG), resulting in 
extended uORFs that overlap, by 23 out-of-frame nucleotides, with the coding region of 
the downstream Luciferase reporter ORF; these overlapped uORFs inhibit translation 
reinitiation (“Overlap both uORFs” construct; Figure 7A). Additionally, each of the 
uORFs was overlapped individually with the main ORF, while the other uORF was 
inactivated by mutation of the corresponding AUG (AUG to UUG) (“Overlap only 
uORF1” and “Overlap only uORF2” constructs; Figure 7A). Luciferase activity from 
these constructs with the extended uORFs was analyzed as before by luminometry 
assays (Figure 7B) and corresponding mRNA levels by RT-qPCR (Figure 7C). Then 
results were normalized to those of the “5’ Leader OK” construct and compared to those 
of the corresponding original constructs.  
The results show a significant decrease in the protein levels when we compare 
expression of the “Overlap both uORFs” construct with those of the “5’ Leader OK” 
construct, in both HeLa (p=0,0002) and HepG2 (p=2,387x10
-9
) cells (Figure 7B). The 
significant decrease in protein levels is also observed between the “Overlap only 
uORF1” and “Only uORF1” constructs, again, in both cell lines (HeLa cells: p= 0,0005; 
HepG2 cells: p= 0,0009). Lastly, comparison of protein levels of the “Overlap only 
uORF2” construct with those of the “Only uORF2” construct, also reveal a reduction in 
protein expression but this time less accentuated relatively to the constructs above 
mentioned, in HepG2 (p=0,0032) and HeLa cells (p=0,0147) (Figure 7B). Thus, this 
data indicate that the uORF2 allows more leaky scanning than the uORF1 since the 
uAUG2 Kozak sequence context is weaker than the uAUG1 that permits less or any 
leaky scanning. As mRNA levels expressed from each construct are similar (Figure 7C), 
we can conclude that our results support a low leaky scanning mechanism, as the 
extended uORFs allow little translation of the main ORF. Also, these data indicate that 
when translation reinitiation is inhibited by the overlapped uORFs, translation of the 
main ORF is significantly inhibited confirming that the translation of the HJV main 
ORF occurs by reinitiation. 
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Figure 7. Preventing translation reinitiation by overlapping of the HJV uORFs with the main ORF decreases 
the Luciferase protein expression levels. (A) Representation of the “Overlap” constructs transiently transfected in 
HeLa and HepG2 cells. “Overlap both uORFs”: 5’ Leader mRNA sequence with both uORFs overlapped with the 
main ORF. “Overlap only uORF1”: 5’ Leader mRNA sequence with only the uORF1 overlapped with the main 
ORF. The uORF2 is inactivated due to mutation of uAUG2 (AUG to UUG). “Overlap only uORF2”: 5’ Leader 
mRNA sequence with only the uORF2 overlapped with the main ORF. The uORF1 is inactivated due to mutation of 
uAUG1 (AUG to UUG). AUG=initiation codon; UAG=stop codon; orange brackets=uORFs; yellow box=Luciferase 
mRNA sequence. (B) Relative Luciferase activity expressed in HeLa and HepG2 cells for each one of the constructs 
represented in (A). Data correspond to the ratio of the enzymatic activity of firefly Luciferase relatively to the Renilla 
Luciferase and normalized for the amount of protein encoded by the “5' Leader OK” construct. Statistical analysis 
was performed using Student’s t test (unpaired, two tails); *statistically significant. (C) Relative mRNA levels of 
each of the constructs, as indicated below the graph, expressed in HeLa cells. Data correspond to the ratio of the 
mRNA levels of firefly Luciferase relatively to Renilla Luciferase and normalized for the amount of mRNA 
expressed by the “5' Leader OK” construct.  
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3.4. There is ribosome stalling in the HJV uORFs  
Knowing that the mechanism by which an uORF can repress translation may 
involve the interaction of the nascent uORF peptide with the ribosome leading to a stall 
of translation [25][34], next we aim to examine if this is applicable to the human HJV 
uORFs. To test the occurrence of this mechanism, we frameshifted the uORFs 
nucleotide sequence by: deletion of a T after the uAUG1 (ATGGCTG to ATGGCG), 
insertion of a C before the uAUG2 (GATAGC to GATACGC), deletion of a T after the 
uAUG2 (ATGTTT to ATGTT) and insertion of a C before the stop codon (TAGGTAG 
to TACGGTAG) (“Sequence Alteration both uORFs” construct; Figure 8A). 
Additionally, each of the uORFs was frameshifted individually, while the other uORF 
was inactivated by mutation of the corresponding AUG (AUG to UUG) (“Sequence 
Alteration only uORF1” and “Sequence Alteration only uORF2” constructs; Figure 8A). 
In all these constructs, the native uAUGs context sequence was maintained. After  
transient transfection of these constructs in HeLa and HepG2 cells, Luciferase activity 
expressed from each one of these constructs was analyzed as before by luminometry 
assays (Figure 8B); the corresponding mRNA levels were quantified by RT-qPCR 
(Figure 8C). Then, results were normalized to those of the “5’ Leader OK” construct 
and compared to those of the corresponding original constructs. 
The results show a significant increase in the protein levels when we compare 
expression of the “Sequence Alteration both uORFs” construct with those of the “5’ 
Leader OK” construct, in both HeLa (p=0,0384) and HepG2 (p=0,0314) cells (Figure 
8B). The significant increase in the protein levels is also observed between the 
“Sequence Alteration only uORF1” and “Only uORF1” constructs in HepG2 
cells(p=0,0070) but not in HeLa cells (p=0,1124) (Figure 8B). Lastly, when we compare 
protein levels of the “Sequence Alteration only uORF2” construct with those of the 
“Only uORF2” construct, we also observe an increase in protein expression of about 4-
fold in HeLa cells (p=0,0001) and a 3,5-fold in HepG2 cells (p=0,0022) (Figure 8B). As 
the mRNA levels from each construct expressed in HeLa cells revealed to be equivalent 
(Figure 8C), alterations in protein levels are exclusively due to changes in translational 
rates. Thus, we observe a derepression of translation when the encoded peptide 
sequence is modified without changing the nucleotide sequence, this allow us to 
conclude that the HJV uORFs may repress translation through ribosome stalling, 
especially when the uORF2 is recognized. 
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Figure 8. Frameshifting the HJV uORFs encoded sequences increases the Luciferase protein expression levels 
(A) Representation of the “Sequence Alteration” constructs transiently transfected in HeLa and HepG2 cells. 
“Sequence Alteration both uORFs”: reading frames of both uORFs are frameshifted through the following 
mutations: deletion of a T after the uAUG1 (ATGGCTG to ATGGCG), insertion of a C before the uAUG2 
(GATAGC to GATACGC) and deletion of a T after the uAUG2 (ATGTTT to ATGTT), insertion of a C before the 
stop codon (TAGGTAG to TACGGTAG). “Sequence Alteration only uORF1”: the reading frame of the uORF1 is 
frameshifted as previously referred in the “Sequence Alteration both uORFs” construct, being the uORF2 inactivated 
due to the mutation of the uAUG2 (AUG to UUG). “Sequence Alteration only uORF2”: the reading frame of the 
uORF2 is modified as referred before in the “Sequence Alteration both uORFs” construct, being inactivated the 
uORF1 due to mutation of the uAUG1 (AUG to UUG). AUG=initiation codon; UAG=stop codon; purple 
brackets=uORFs with the frameshifted encoded sequence; yellow box= Luciferase mRNA sequence; arrow= deletion 
or insertion of a nucleotide (nt). (B) Relative Luciferase activity expressed in HeLa and HepG2 cells for each of the 
constructs indicated below the chart. Data correspond to the ratio of the enzymatic activity of firefly Luciferase 
relatively to the Renilla Luciferase and normalized for the amount of protein encoded by the construction “5' Leader 
OK”. Statistical analysis was performed using Student’s t test (unpaired, two tails); *statistically significant. (C) 
Relative mRNA levels of each construct, as indicated, expressed in HeLa cells. Data correspond to the ratio of the 
mRNA levels of firefly Luciferase relatively to Renilla Luciferase and normalized for the amount of mRNA 
expressed by the “5' Leader OK” construct. 
 
 
 
0
1
2
3
4
5
6
7
8
9
10
5' Leader OK Only uORF1 Only uORF2 uORFs KO Sequence 
Alteration both 
uORFs
Sequence 
Alteration only 
uORF1
Sequence 
Alteration only 
uORF2
R
e
la
ti
ve
Lu
ci
fe
ra
se
 a
ct
iv
it
y
(f
ir
e
fl
y/
R
en
il
la
)
HeLa
HepG2
Sequence Alteration both uORFs 
Sequence Alteration only uORF1
Sequence Alteration only uORF2 
A
B
C
* * *
* *
0
1
2
5' Leader OK Only uORF1 Only uORF2 uORFs KO Sequence 
Alteration 
both uORFs
Sequence 
Alteration 
only uORF1
Sequence 
Alteration 
only uORF2
R
e
la
ti
ve
m
R
N
A
le
ve
ls
(f
ir
e
fl
y/
R
en
il
la
)
HeLa
uORF1
uORF2
UAGuAUG1 uAUG2 AUG
5’ Leader region of the HJV mRNA
LUCIFERASE
-1nt +1nt -1nt +1nt
uORF1
UAGuAUG1 UUG AUG
LUCIFERASE
-1nt +1nt -1nt +1nt
uORF2
UAGUUG uAUG2 AUG
LUCIFERASE
-1nt +1nt
28 
 
Since the “Sequence Alteration only uORF2” construct expresses protein levels 
similar to those of the “uORFs KO” construct, we hypothesized that this result could be 
due to the fact that the uORFs present in the “Sequence Alteration” constructs are 
weakly our not at all recognized by the ribosome despite their uAUGs contexts being 
unaltered. To test this hypothesis, we took advantage of knowing that the overlap of 
these uORFs with the downstream main ORF inhibit translation reinitiation, as 
previously shown in figure 7, confirming their recognition by the ribosomes. Therefore, 
we mutated the stop codon of all “Sequence Alteration” constructs to a sense codon 
(UAG to AAG) resulting again in extended uORFs that overlap by 23 nucleotides out-
of-frame with the coding region of the downstream Luciferase reporter ORF (“Sequence 
Alteration both uORFs mut stop”, “Sequence Alteration only uORF1 mut stop” and 
“Sequence Alteration only uORF2 mut stop” Figure 9A). Thus, we expressed these 
constructs in HeLa and HepG2 cells as before and the corresponding Luciferase activity 
was assessed by luminometry assays (Figure 9B). Results were normalized to those of 
the “5’ Leader OK” construct and compared to those of the corresponding original 
constructs. 
Our data show a decrease in the protein levels when we compare the expression 
of the “Sequence Alteration both uORFs mut stop” construct with those of the 
“Sequence Alteration both uORFs” construct in both HeLa (p=0,0013) and HepG2 cells 
(p=0,0045) (Figure 9B). The significant decrease in protein levels is also observed 
between the “Sequence Alteration only uORF1 mut stop” and “Sequence Alteration 
only uORF1” constructs, again, in both cell lines (HeLa cells: p=3,17x10-5; HepG2 
cells: p=0,0014; Figure 9B). Lastly, when compared protein levels of the “Sequence 
Alteration only uORF2 mut stop” construct with those of the “Sequence Alteration only 
uORF2” construct, we also observed a significant reduction in protein expression in 
HeLa (p=0,0001) and HepG2 (p=0,0002) cells (Figure 9B). Therefore, the data show 
that all three “Sequence Alteration mut stop” constructs are expressed at significantly 
lower protein levels as those from the “Overlap” constructs (Figure 9B versus Figure 
7B). These results demonstrate that the “Sequence Alteration” constructs have the same 
competence to be recognized by the ribosome as the native ORFs and thus we can 
conclude that in the native human HJV uORFs there is ribosome stalling. 
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Figure 9. The uORFs present in the mRNA encoded by the “Sequence Alteration” constructs support low 
leaky scanning and they have the same ability to be recognized by the ribosome as the native uORFs. (A) 
Representation of the “Sequence Alteration mut stop” constructs expressed in HeLa and HepG2 cells. “Sequence 
Alteration both uORFs mut stop”: The stop codon of the uORFs present in the “Sequence Alteration both uORFs” 
construct is mutated (UAG to AAG). “Sequence Alteration only uORF1 mut stop”: The stop codon of the uORF1 
present in the “Sequence Alteration only uORF1” construct is mutated (UAG to AAG). “Sequence Alteration only 
uORF2 mut stop”: The stop codon of the uORF2 present in the “Sequence Alteration only uORF2” construct is 
mutated (UAG to AAG). AUG=initiation codon; UAG=stop codon; purple brackets=uORFs with the frameshifted 
encoded sequence; yellow box=Luciferase mRNA sequence; arrow=deletion or insertion of a nucleotide (nt). (B) 
Relative Luciferase activity of each of the constructs (represented in A) expressed in HeLa and HepG2 cells, as 
indicated below the graph. Data correspond to the ratio of the enzymatic activity of firefly Luciferase relatively to the 
Renilla Luciferase and normalized for the amount of protein encoded by the “5' Leader OK” construct. Statistical 
analysis was performed using Student’s t test (unpaired, two tails); *statistically significant. 
 
 
3.5. The HJV uORFs encoded amino acid sequence is conserved among 
species 
As referred before, some uORFs are conserved among species, which reflects 
their functional role. In order to verify if some sequence in the HJV encoded peptide is 
conserved among different species, which might indicate its role in translational 
regulation through the mechanism of ribosome stalling, we analysed the amino acid 
sequence alignment of the Homo sapiens HJV uORFs with those of the following 
species: Nomascus leucogenys, Gorilla gorilla, Macaca mulatta, Pan troglodytes, 
Pongo abelli, Felis cactus, Canis familiaris, Mus musculus and Rattus norvegicus 
(Table 1). The alignment revealed that in all analysed species, both uAUGs and uORFs 
are highly conserved. This high identity of uAUGs and uORFs may reflect an important 
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evolutionary selection pressure, revealing their role in translation regulation of HJV 
protein expression. Furthermore, it is important to notice that the nucleotide sequence is 
also conserved among the analysed apes except from Pongo abelli that differs in only 
two nucleotides resulting in the only two different amino acids (Table 1). Relatively to 
the other animal species compared, namely, Felis cactus and Canis familiaris, we 
observed less amino acid conservation albeit almost all amino acids are maintained. 
Considering the rodents sequences, it is observed a divergence in some amino acids, 
comparatively to Homo sapiens. Furthermore, both species, Mus musculus and Rattus 
norvegicus, do not share the same stop codon. However, as mentioned before these 
species have the uAUGs in the same position as the human uAUGs what led us to think 
that these uORFs in rodents have a different structure. Nevertheless, most of the 
analysed species share highly conserved HJV uORFs, and this amino acid conservation 
may reveal a specific function of the uORFs encoded peptides in the HJV translational 
regulation. 
 
 
Table 1. The uORFs encoded amino acid sequence alignment among several species and “sequence alteration” 
peptide encoded by “Sequence alteration only uORF1” construct. The letters represent the amino acids. The 
colours indicate the family of the amino acid: yellow=non polar, green=polar, pink=acid, blue=basic, gray=stop 
codon. Last column indicates the percentage (%) of conservation, relatively to the human HJV uORFs. 
Homo sapiens 
 
M A G E L D S R V M F D L W K H H L Q G F R S K F T R Stop 100% 
“Sequence Alteration 
both uORFs”  
M A E N W I R R V M L T S G N I T Y R A S G Q N S L R Stop 18% 
Nomascus leucogenys M A G E L D S R V M F D L W K H H L Q G F R S K F T R Stop 100% 
Gorilla Gorilla M A G E L D S R V M F D L W K H H L Q G F R S K F T R Stop 100% 
Macaca mulatta M A G E L D S R V M F D L W K H H L Q G F R S K F T R Stop 100% 
Pan troglodytes M A G E L D S R V M F D L W K H H L Q G F R S K F T R Stop 100% 
Pongo abelli M T G E L D S R V M S D L W K H H L Q G F R S K F T R Stop 93% 
Felis cactus M A G G L D I R V M F D P W K H P L Q E V R S K F T R Stop 79% 
Canis familiaris M A G E L D I R V M F V L W K H P L Q E V R S K F T R Stop 82% 
Mus musculus M A R E P S I R V M L D L G K H H R S T Q R N S L G Stop 
 
43% 
Rattus norvegicus M A G E P G I R V M L D L G K H Q I S S S D R R S S T R 39% 
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3.6. The HJV uORF1 does not allow efficient ribosome stalling  
Since the HJV uORFs encoded amino acids sequences revealed to be highly 
conserved along species, which points out their regulatory role, we decided to study the 
influence of each one of the HJV uORFs encoded peptides in ribosome stalling. In this 
chapter we will discuss the influence of the uORF1 alone. To address this question, we 
divided the uORF1 into two regions: first we tested the region between the uAUG1 and 
the uAUG2, and then the region between the uAUG2 and the stop codon, which is 
common to the uORF2. 
 
3.6.1. The sequence between the uAUG1 and the uAUG2 of the HJV uORFs 
as well as the encoded peptide, are not involved in the ribosome stalling 
To better understand how ribosome stalling occurs in the human HJV uORFs, 
our first approach was to study the influence of the codons of the region between both 
uAUGs (uAUG1 and uAUG2). Since some amino acids are common (in bold) between 
the native encoded peptide – MAGELDSRV – and that one (MAENWIRRV; Table 1) 
expressed from construct “Sequence alteration only uORF1” (Figure 8), we only 
analysed the influence of the codons encoding different amino acids (codons encoding 
GELDS). In other words, to test how the codons between both uAUGs of the HJV 
uORF1 are involved in the ribosome stalling, the codons 3 to 7 (that encode to GELDS) 
of the “Only uORF1” construct were mutated individually by site directed mutagenesis 
to a synonymous codon with comparable frequency (Table 2). After transient 
transfection of HeLa and HepG2 cells with the corresponding constructs, their protein 
levels were analysed by luminometry assays. Results were normalized to those of the 
“Only uORF1” construct (Figure 10).  
 
Table 2. In each construct, each codon was individually mutated to a synonym codon, in the sequence between 
the uAUG1 and uAUG2. The codons in the nucleotide sequence between the uAUG1 and uAUG2, 
GGAGAATTGGATAGC, were individually changed to test the codon influence in the ribosome stalling. The codon 
frequencies were maintained as possible. The underlined letters represent the mutated codon.   
Individual codon change Nucleotide sequence from uAUG1 to uAUG2 
Amino acid 3 GGGGAATTGGATAGC 
Amino acid 4 GGAGAGTTGGATAGC 
Amino acid 5 GGAGAACTTGATAGC 
Amino acid 6 GGAGAATTGGACAGC 
Amino acid 7 GGAGAATTGGATTCC 
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Results show that, in HeLa cells, a significant decrease in the protein levels 
occurs, when codons 3, 4, or 5 (p=6,64x10
-5
; p=0,0016; p=0,0007, respectively) of 
uORF1 are mutated to a synonymous codon (Figure 10). However, in HepG2 cells, all 
constructs are expressed at similar levels and comparable to those of the normal control 
(“Only uORF1” construct). In any case we do not observe a derepression of translation 
of the downstream main Luciferase ORF. Therefore, these results suggest that the 
nucleotide sequence between both HJV uAUGs is not involved in the ribosome stalling.  
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Figure 10. Substituting individual codons by a synonym codon in the sequence between uAUG1 and uAUG2 of 
the uORF1 does not derepress translation of the main ORF and thus it does not affect ribosome stalling. 
Relative Luciferase activity expressed in HeLa and HepG2 cells for each of the constructs represented in the table 2. 
Data correspond to the ratio of the enzymatic activity of firefly Luciferase relatively to the Renilla Luciferase and 
normalized for the amount of protein encoded by the construction “Only uORF1”. Statistical analysis was performed 
using Student’s t test (unpaired, two tails); *statistically significant. 
 
 
Next, we analysed the influence of the amino acids encoded by the same region, 
between the uAUG1 and the uAUG2. For that, we individually mutated each one of the 
codons encoding for the GELDS peptide to Alanine, which is a common non basic 
amino acid (Table 3) [46]. Since these mutations alter the amino acid family of the 
native amino acids 4, 6 and 7, we also introduced individual mutations in these codons 
in a way to maintain the same amino acid family (Table 4), and, thus, to guarantee the 
maintenance of the peptide proprieties. For all mutations, we obtained codons encoding 
amino acids with a frequency similar to those of the normal control. After transient 
transfection of HeLa and HepG2 cells with the corresponding constructs, their protein 
levels were analysed by luminometry assays. Then results were normalized to those of 
the “Only uORF1” construct (Figure 11).  
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Table 3. Each codon, in the sequence between the uAUG1 and uAUG2 of the uORF1, was individually 
mutated to the Alanine (underlined) to test the amino acid influence in the ribosome stalling. The letters 
represents the amino acids. 
Individual codon mutation to codify Alanine  Amino acid sequence from uAUG1 to 
AUG2 
Amino acid 3   A E L D S   
Amino acid 4   G A L D S   
Amino acid 5   G E A D S   
Amino acid 6   G E L A S   
Amino acid 7   G E L D A   
 
 
 
 
 
Table 4. Codons 3, 6 and 7 were individually mutated (underlined) to an amino acid of the same type, in the 
sequence between the uAUG1 and uAUG2 that codifies for GELDS, to test the amino acid influence in the 
ribosome stalling. The letters represents the amino acids. 
Individual codon mutation 
to codify the same type of amino acid  
Amino acid sequence from uAUG1 to 
uAUG2 
Amino acid 4   G D L D S   
 Amino acid 6   G E L E S   
 Amino acid 7   G E L D T   
 
 
The obtained data show that when an Alanine is codified by codons 4, 5, 6 or 7 
of the HJV uORF1, a significant decrease in the protein levels occurs, when compared 
to the protein levels expressed from the “Only uORF1” construct, in HeLa cells 
(p=0,0024 p=0,0027; p=0,0032 and p=0,0105, respectively), (Figure 11A). 
Additionally, no alteration in protein expression was observed when the same constructs 
were expressed in HepG2 cells (Figure 11A). When we analyzed the mutant constructs 
that express the reporter mRNAs, which encode between uAUG1 and uAUG2 amino 
acids of the same family (table 4), we observed, in HeLa cells, a significant decrease of 
the protein levels, when the amino acid 6 is mutated (p=0,0164) (Figure 11B). In 
HepG2 cells, we did not observe any significant effect in protein levels, when amino 
acids 4, 6 and 7 were altered to another one of the same family (Figure 11B). This full 
set of data shows that these amino acids substitutions in the region between uAUG1 and 
uAUG2 of the human HJV uORF1 do not induce a derepression of translation of the 
downstream main ORF. Therefore, the peptide encoded by the sequence between the 
uAUG1 and uAUG2 of the HJV uORF1 is not responsible for the ribosome stalling.  
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Figure 11. Amino acids encoded by the sequence between uAUG1 and uAUG2 of the HJV uORF1 are not 
responsible for the ribosome stalling. (A) Substituting individual amino acids for common amino acids (Alanine) in 
the peptide encoded by the sequence between uAUG1 and uAUG2 of the uORF1 does not derepress translation. 
Relative Luciferase activity expressed in HeLa and HepG2 cells for each of the constructs represented in the table 3. 
(B) Substituting individual amino acids for amino acids of the same family in the peptide encoded by the sequence 
between uAUG1 and uAUG2 of the uORF1 does not derepress translation. Relative Luciferase activity expressed in 
HeLa and HepG2 cells for each of the constructs indicated below the graphs. Data correspond to the ratio of the 
enzymatic activity of firefly Luciferase relatively to the Renilla Luciferase and normalized for the amount of protein 
expressed from “Only uORF1” construct. Statistical analysis was performed using Student’s t test (unpaired, two 
tails); *statistically significant.  
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3.6.2. The peptide encoded by the HJV uORF1 does not induce ribosome 
stalling 
Since the region between the uAUG1 and the uAUG2 does not seem to be 
responsible for the ribosome stalling, we next analysed the effect of the two regions 
defined for the uORF1 peptide separately. For that we applied the same strategy of 
frameshift as in the “Sequence Alteration only uORF1” construct (Figure 8; chapter 
3.4). We frameshifted the uORF1 in the “Only uORF1” construct by a deletion of a T 
after the uAUG1 (ATGGCTG to ATGGCG) and an insertion of a C before the uAUG2 
(GATAGC to GATACGC), maintaining the native sequence between the uAUG2 and 
the stop codon (“Hybrid 1” construct; Figure 12A). Additionally, we frameshifted the 
uORF1 in the “Only uORF1” construct, between the AUG2 and the stop codon by a 
deletion of a T after the uAUG2 (ATGTTT to ATGTT) and an insertion of a C before 
the stop codon (TAGGTAG to TACGGTAG), maintaining the native sequence between 
the uAUG1 and the uAUG2 (“Hybrid 2” construct; Figure 12A). After transient 
transfection of HeLa and HepG2 cells with the corresponding constructs, their protein 
levels were analysed by luminometry assays. Then results were normalized to those of 
the “Only uORF1” construct (Figure 12B).  
Results show that the “Hybrid 1” construct is expressed at the same protein 
levels as the “Only uORF1” construct in both HeLa and HepG2 cells (Figure 12B). 
However, “Hybrid 2” construct shows a significant decrease in the protein levels when 
we compare expression of the “Only uORF1” construct in both HeLa (p=0,0005) and 
HepG2 (0,0078) cells (Figure 12B). Of note, in none of the cases there is an increase of 
protein levels. These data confirm that the peptide encoded by the uORF1 has no 
capability to stall the ribosome when is translated, which is in accordance with the data 
shown above.  
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Figure 12. The N- or C-terminal regions of the peptide encoded by the HJV uORF1 are not strongly involved 
in the ribosome stalling. The peptide sequence alteration in the two regions of the uORF1 seems not to be 
related to the ribosome stall. (A) Representation of the “Hybrid” constructs expressed in HeLa and HepG2 cells, 
used to test if the peptide sequence alteration in the two regions of the “Only uORF1” construct influence the 
ribosome stall. “Hybrid 1”: the uORF1 of the “Only uORF1” construct is frameshifted between the uAUG1 and 
uAUG2 by a deletion of a T after the uAUG1 (ATGGCTG to ATGGCG) and an insertion of a C before the uAUG2 
(GATAGC to GATACGC). The region between uAUG2 and the stop codon is maintained. “Hybrid 2”: the uORF1 
of the “Only uORF1” construct is frameshifted between the uAUG2 and the stop codon by a deletion of a T after the 
uAUG2 (ATGTTT to ATGTT) and an insertion of a C before the stop codon (TAGGTAG to TACGGTAG). The 
region between the uAUG1 and the uAUG2 is maintained. AUG=initiation codon; UAG=stop codon; purple 
bracket=uORF1 with the encoded sequence frameshifted; orange bracket=native uORF1 sequence; yellow 
box=Luciferase mRNA sequence; arrow=deletion or insertion of a nucleotide (nt). (B) Relative Luciferase activity 
expressed in HeLa and HepG2 cells for each of the constructs represented in (A). Data correspond to the ratio of the 
enzymatic activity of firefly Luciferase relatively to the Renilla Luciferase and normalized for the amount of protein 
encoded by the “Only uORF1” construct. Statistical analysis was performed using Student’s t test (unpaired, two 
tails); *statistically significant. 
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3.7. The C-terminal region of the HJV uORF2 encoded peptide seems to be 
responsible for ribosome stalling 
To test if the peptide encoded by the HJV uORF2 is involved in the observed 
ribosome stalling, we performed by site-directed mutagenesis, several mutations in the 
“Only uORF2” construct in order to analyse the effect of consecutively modify the 
amino acids encoded by uORF2 into the “Sequence Alteration only uORF2” construct 
(Table 5). The obtained constructs (Table 5) were used to transiently transfect HeLa 
cells. 
 
Table 5. Consecutive mutagenesis of the uORF2 encoded peptide sequence. The uORF2 encoded peptide 
sequence was consecutively mutated to gradually obtain the “Sequence Alteration Only uORF2” encoded peptide 
(underlined bold). The letters represents the amino acids. 
Peptide sequence encoded 
from the “Only uORF2” 
construct 
M F   D  L   W   K  H H L  Q  G F  R S K F T R Stop 
 “Sequence Alteration only 
uORF2”  
M L T S G N I T Y R A S G Q N S L R Stop 
Consecutive sequence 
alteration 2 
M L  D  L   W   K  H H L  Q  G F  R S K F T R Stop 
Consecutive sequence 
alteration 3 
M L T  L   W   K  H H L  Q  G F  R S K F T R Stop 
Consecutive sequence 
alteration 4 
M L T S  W   K  H H L  Q  G F  R S K F T R Stop 
Consecutive sequence 
alteration 5 
M L T S G  K  H H L  Q  G F  R S K F T R Stop 
Consecutive sequence 
alteration 6 
M L T S G N H H L  Q  G F  R S K F T R Stop 
Consecutive sequence 
alteration 7 
M L T S G N I H L  Q  G F  R S K F T R Stop 
Consecutive sequence 
alteration 8 
M L T S G N I T L  Q  G F  R S K F T R Stop 
Consecutive sequence 
alteration 9 
M L T S G N I T Y  Q  G F  R S K F T R Stop 
Consecutive sequence 
alteration 10 
M L T S G N I T Y R G F  R S K F T R Stop 
Consecutive sequence 
alteration 11 
M L T S G N I T Y R A F  R S K F T R Stop 
Consecutive sequence 
alteration 12 
M L T S G N I T Y R A S R S K F T R Stop 
Consecutive sequence 
alteration 13 
M L T S G N I T Y R A S G S K F T R Stop 
Consecutive sequence 
alteration 14 
M L T S G N I T Y R A S G Q K F T R Stop 
Consecutive sequence 
alteration 15 
M L T S G N I T Y R A S G Q N F T R Stop 
Consecutive sequence 
alteration 16 
M L T S G N I T Y R A S G Q N S T R Stop 
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Luciferase activity from these constructs was analyzed as before by luminometry assays 
and the results were normalized to those of the “Only uORF2” construct (Figure 12B).  
Despite only two experiences had been performed, the results show an increase 
of the proteins levels when we compare expression of the constructs with the 
consecutive sequence alteration from the amino acid 7 to 16 to those of the “Only 
uORF2” construct, which means that the amino acids encoded by the new codons 7 to 
16 have less ability to stall the ribosome (Figure 13). Moreover, the increase in protein 
levels is more substantial when the consecutive alteration of amino acids reaches the 
positions 16 and the 17, which are the codons contiguous to the stop codon (Figure 13). 
These results suggest that the C-terminal region of the peptide encoded by the HJV 
uORF2 have the ability to interact with the translation machinery and to stall the 
ribosome. 
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4. Discussion 
 
The regulation of gene expression is a field of study that has shown a high 
complexity and diversity of processes responsible for the high plasticity of organisms to 
adapt and fit to several situations. Despite the transcriptional regulation has been called 
as the controller of gene expression, the post-transcriptional regulation has gained 
relevance and has been shown to contribute to this control with a variety of mechanisms 
that allow modulation of expression in a faster and more volatile manner [47] [26]. 
Small uORFs are an example of elements acting in cis, involved in post-
transcriptional regulation. The 5’ leader mRNA sequences can contain uORFs that 
appear to be involved in the translation inhibition of the main ORF [34]. These uORFs 
are present in several classes of genes such as oncogenes and cell growth and 
differentiation genes [34][35]. An uAUG present in the 5’ leader mRNA sequence can 
be recognized for translation initiation, diminishing the translation of the downstream 
ORF and consequently reducing the levels of the main synthesized protein [25]. In 
genes bearing uORFs, the translation of the main ORF can be achieved by leaky 
scanning or reinitiation that guarantees the protein production [25][34].  
The aim of this study was to investigate how the presence of the two uORFs in 
the transcript of the human HJV affects the translation of the gene product. To 
accomplish that, we used an experimental system that takes advantage of a reporter 
construct in which the human HJV 5’ leader sequence was cloned in a way to be bound 
to the reporter ORF of the firefly Luciferase, allowing measuring its effect on the 
reporter Luciferase protein synthesis. After expressing this construct (and its mutants) in 
cultured cells, quantification of the Luciferase protein levels was performed by 
luminometry assays. As already referred, the 5’ leader sequence of the human HJV 
mRNA includes one uORF with 28 codons (uORF1) and another with 19 codons 
(uORF2), sharing both the same stop codon. Several mutants of the 5’ leader sequence 
were also cloned and tested to assess the ability of reinitiation, leaky scanning and 
ribosome stalling in the HJV transcript. The obtained results were analysed taking into 
account the corresponding mRNA levels, acquired by RT-qPCR, to assure that the 
observed effects in protein expression are a result of translational regulation. We 
performed this work in two cells lines: one cell line derived from a human 
hepatocellular carcinoma (HepG2 cells), as human physiological hepcidin and HJV 
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mRNAs are specifically expressed in liver, and another derived from human cervical 
cancer (HeLa cells), where neither proteins are expressed. 
Our results revealed that uORF1 and uORF2 are indeed functional in the HJV 
transcript, preventing the main ORF to be translated with fully competence (Figure 5). 
The uORF1 is the major repressor of translation of the main ORF. This competence was 
expected since the uAUG1 lies in an optimal AUG sequence context, having the 
suitable nucleotides in the -3 and +4 positions. The uAUG1 optimal context leads to the 
recognition of uORF1 by the ribosome in most rounds of translation, reducing the 
production of the functional protein. On the other hand, the uORF2 represses translation 
of the HJV protein with less efficiency due to its weaker AUG sequence context (it 
lacks the appropriate nucleotide in the position +4). However, it is important to notice 
that when both uORFs are present in the transcript, their effect in translation 
suppression is superior to the sum of their individual effects. So, when both uORFs are 
in the 5’ leader mRNA sequence a synergetic effect seems to occur, which might 
consists in a stronger barrier to the ribosome accessing to the main AUG. These effects 
are observed in both HeLa and HepG2 cells and thus they are not tissue specific. 
However, the synergy between the uORFs seems to be superior in HepG2 cells.  
To test the ability of the ribosome to reinitiate after the uORFs translation, the 
uAUGs contexts were improved, to prevent the leaky scanning (Figure 6). Both uAUGs 
Kozak contexts were improved together, as well as individually. The results obtained 
both in HeLa and HepG2 cells, revealed that reinitiation is the major mechanism 
responsible for the main AUG recognition. Since the reinitiation depends on the length 
of intercistronic region, on the secondary structures of the transcript and on the uORF 
length [24][25][34], our results suggest that the human HJV intercistronic region has 
favourable features for reinitiation. Also, the uORFs properties (such as length and 
translation rate) seem to be appropriate for reinitiation to occur.  
To test for the occurrence of leaky scanning on the HJV transcript, constructs 
with the disrupted uORFs stop codon, were tested (Figure 7). In these constructs the 
reinitiation is prevented due to the uORFs overlap with the firefly Luciferase cistron. 
Therefore, the main AUG can only be achieved by leaky scanning. The results revealed 
a low leaky scanning occurrence in the HJV uORFs, both in HeLa and HepG2 cells. 
This low leaky scanning can be justified by the uAUGs good contexts, specially the 
uAUG1 that has the optimal Kozak context, been recognized most of the times by the 
scanning ribosome. On the other hand, when only the uORF2 is present, the protein 
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levels are superior, showing that is more prompt to leaky scanning, due to its weaker 
AUG sequence context. These results put in evidence that the AUG sequence context 
has indeed a main role in the AUG recognition and thus, in the translational rate. In 
addition, as it is seen here for the human HJV transcript, the evolutionary conservation 
and selection of uAUG and uORFs reflects indeed their role in the translational control.  
The ribosome stalling causes translational repression since the ribosome 
blockade impedes other ribosomes to translate the mRNA [34][38]. To test if the HJV 
mRNA suffers ribosome stalling during translation of its uORFs, we analysed a set of 
constructs in which uORFs were changed by frameshift, allowing the synthesis of 
different uORFs encoded peptides, without changing the uORFs nucleotide sequence 
(Figure 8). Our results revealed that when the amino acid sequence changes, an increase 
of the protein levels occurs, especially when the 5’ leader sequence of the HJV mRNA 
only carries the uORF2. This effect is observed in both cell lines. However, when we 
analyse the effect of altering the peptide sequence encoded by the uORF1, we see a 
significant increase in protein levels in the HepG2 cells but not in HeLa cell line, which 
might indicate for a tissue specific effect. Nevertheless, the results from HepG2 cells 
still need to be normalized to the corresponding mRNA levels. To unequivocally prove 
that the observed effects in protein levels are a result of the uORFs recognition by the 
ribosome, we further tested the effect of disrupting the uORFs stop codon (Figure 9). 
The results confirmed the maintenance of low leaky scanning previously observed in 
the wild-type HJV 5’ leader mRNA sequence. Therefore, we can conclude that the 
uORFs in the “Sequence alteration” constructs (Figure 8) have the same capacity to be 
recognized as the native uORFs. These results may indicate that during the process of 
translation in the HJV uORFs, there is ribosome stalling, which is dependent on the 
synthesized encoded peptide; furthermore, it seems that this ribosome stalling is 
stronger when uORF2 is translated. To better validate the occurrence of ribosome 
stalling, we compared the HJV uORFs encoded peptide sequences among different 
species (Table 1). Indeed, we verified a high conservation of amino acids, especially in 
primates, which is in accordance with our data showing that human HJV uORFs control 
translation of the downstream main ORF.   
Next, we investigated how the uORF1 encoded peptide is involved in ribosome 
stalling (Figures 10-12). Results have shown that ribosome stalling does not depend on 
the nucleotide sequence of the region between uAUG1 and uAUG2 of the uORF1, 
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neither on the corresponding encoded amino acids sequence. Moreover, the results 
shown that the entire peptide encoded by the uORF1 is not able to stall the ribosome.  
At the end, we also analysed the effect of the uORF2 encoded peptide in the 
ribosome stalling (Figure 13). The results revealed that the C-terminal part of this 
peptide has the ability to stall the ribosome, since it was observed an increase of the 
protein levels when this region was modified. Moreover, it seems that the region closest 
to the stop codon has the higher ability to stall the ribosome, since when the last codons 
are mutated to codify different amino acids, protein levels considerably increase.  
Our results support the notion that when the ribosome translates the uORF2, 
there is the ability for ribosome stalling; however, when the correspondent region is 
translated in the uORF1, ribosome stalling does not occur. Why does the same region 
act in a different way in the two uORFs? The answer might be the length and/or the 
secondary structure of the encoded peptide. It is possible that the two encoded peptides 
may interact with the ribosome in a different way, depending on their lengths and/or 
secondary structures, when the ribosome reaches the final codons. By being shorter, the 
uORF2 encoded peptide might be more effective in interacting with the translation 
machinery, and thus might stall the ribosome with more efficiency. An interesting 
future experience would be to test whether the human HJV transcript is a natural target 
for NMD and to correlate the results with the fact that only uORF2 allows for ribosome 
stalling. 
Understanding the mechanisms involved in the human HJV protein expression is 
extremely important to identify potential targets for therapeutic interventions in diseases 
associated with iron metabolism. In this manner, this study might contribute to a better 
knowledge of the HJV role in the iron metabolism and might contribute to future 
therapies. One potential example for future therapeutics would be the use of a drug with 
the ability to make the ribosome bypass the HJV uORFs increasing the HJV protein 
expression and consequently the hepcidin levels, which could decrease the iron 
absorption in HH patients.  
In future experiences it would be interesting to investigate the biological 
function of the human HJV uORFs. For that, it could be analysed if the HJV uORFs 
have the ability to respond to certain cellular stresses, such as iron overload or 
depletion, and hypoxia.  
In conclusion, the present study demonstrates that the uORFs present in the 5’ 
leader sequence of the human HJV transcript are functional in different tissues, 
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negatively regulating translation. We also concluded that the main AUG is recognized 
by translation reinitiation, because the uORFs suffer low leaky scanning, due to the 
strong uAUGs sequence contexts. This study also revealed that the ribosome stalling 
depends on the amino acid sequence of the uORF2. We believe that the two uORFs 
have different purposes: the uORF1 is the main responsible for the translational 
repression thanks to its frequent recognition; the uORF2 might function as a fail-safe 
element in situations in which uORF1 is not recognized by the ribosome. When this 
condition occurs, ribosome stalling is triggered to repress translation of the downstream 
main ORF.   
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6. Annex  
 
Table I – Sequence of the oligonucleotides used in the corrent work (*: removed 
nucleotide; Bold: inserted nucleotide; Underlined: substituted nucleotide). 
Primers for Site-directed mutagenesis 
Primer 5’ to 3’ sequence 
AUG1 better Kozak S GAGTAGGGAACCATGGCTGGAGAATTGG  
AUG1 better Kozak AS CCAATTCTCCAGCCATGGTTCCCTACTC 
AUG2 better Kozak S ATTGGATAGCAGAGCCATGGTTGACCTCTGG 
AUG2 better Kozak AS CCAGAGGTCAACCATGGCTCTGCTATCCAAT 
overlap stop mut S GGTCAAAATTCACTAGGAAGGAGGGTCATCAGCTGG 
overlap stop mut AS CCAGCTGATGACCCTCCTTCCTAGTGAATTTTGACC 
RS Pep1 S GAGTAGGGAATCATGGC*GGAGAATTGG 
RS Pep1 AS CCAATTCTCC*GCCATGATTCCCTACTC 
RS Pep1 AUG1 mut S GAGTAGGGAATCTTGGC*GGAGAATTGG  
RS Pep1 AUG1 mut AS CCAATTCTCC*GCCAAGATTCCCTACTC 
RS Pep2 S ATTGGATACGCAGAGTAATGTT*GACCTCTGG 
RS Pep2 AS CCAGAGGTC*AACATTACTCTGCGTATCCAAT 
RS Pep2 AUG2 mut S ATTGGATACGCAGAGTATTGTT*GACCTCTGG 
RS Pep2 AUG2 mut AS CCAGAGGTC*AACAATACTCTGCGTATCCAAT  
RS Pep final overlap S CGGTCAAAATTCACTACGGTAGGAGGG 
RS Pep final overlap AS CCCTCCTACCGTAGTGAATTTTGACCG 
Sequence Alteration mut stop S CGGTCAAAATTCACTACGGAAGGAGGGTCATCAGC 
Sequence Alteration mut stop AS GCTGATGACCCTCCTTCCGTAGTGAATTTTGACCG 
Change to Alanine 3 S GGGAATCATGGCTGCAGAATTGGATAGC 
Change to Alanine 3 AS GCTATCCAATTCTGCAGCCATGATTCCC 
Change to Alanine 4 S ATCATGGCTGGAGCTTTGGATAGCAGAG 
Change to Alanine 4 AS CTCTGCTATCCAAAGCTCCAGCCATGAT 
Change to the same amino acid type 4 S ATCATGGCTGGAGACTTGGATAGCAGAG  
Change to the same amino acid type 4 AS CTCTGCTATCCAAGTCTCCAGCCATGAT 
Change to Alanine 5 S CATGGCTGGAGAAGCAGATAGCAGAGTA 
Change to Alanine 5 AS TACTCTGCTATCTGCTTCTCCAGCCATG 
Change to Alanine 6 S GGCTGGAGAATTGGCTAGCAGAGTAATG 
Change to Alanine 6 AS CATTACTCTGCTAGCCAATTCTCCAGCC 
Change to the same amino acid type 6 S GCTGGAGAATTGGAAAGCAGAGTAATGT 
Change to the same amino acid type 6 AS ACATTACTCTGCTTTCCAATTCTCCAGC 
Change to Alanine 7 S CTGGAGAATTGGATGCTAGAGTAATGTTTGAC 
Change to Alanine 7 AS GTCAAACATTACTCTAGCATCCAATTCTCCAG 
Change to the same amino acid type 7 S TGGAGAATTGGATACCAGAGTAATGTTT 
Change to the same amino acid type 7 AS AAACATTACTCTGGTATCCAATTCTCCA 
Individual codon  change 3 S GGAATCATGGCTGGGGAATTGGATAGCA 
Individual codon  change 3 AS TGCTATCCAATTCCCCAGCCATGATTCC 
50 
 
Individual codon  change 4 S ATCATGGCTGGAGAGTTGGATAGCAGAG 
Individual codon  change 4 AS CTCTGCTATCCAACTCTCCAGCCATGAT 
Individual codon  change 5 S TCATGGCTGGAGAACTTGATAGCAGAGTAAT 
Individual codon  change 5 AS ATTACTCTGCTATCAAGTTCTCCAGCCATGA 
Individual codon  change 6 S GCTGGAGAATTGGACAGCAGAGTAATGTT 
Individual codon  change 6 AS AACATTACTCTGCTGTCCAATTCTCCAGC 
Individual codon  change 7 S GCTGGAGAATTGGATTCCAGAGTAATGTTTG 
Individual codon  change 7 AS CAAACATTACTCTGGAATCCAATTCTCCAGC 
Hybrid 1 S ATTGGATACGCAGAGTATTGTTTGACCTCTGGAA 
Hybrid 1 AS TTCCAGAGGTCAAACAATACTCTGCGTATCCAAT 
Hybrid 2 S ATTGGATAGCAGAGTATTGTT*GACCTCTGGAA 
Hybrid 2 AS TTCCAGAGGTC*AACAATACTCTGCTATCCAAT  
Pre Consecutive Sequence Alteration AS GAATTGGATAGCAGAGTAATGTT*GACCTCTGGAA  
Pre Consecutive Sequence Alteration S TTCCAGAGGTC*AACATTACTCTGCTATCCAATTC 
Consecutive Sequence Alteration 11 S GATAGCAGAGTAATGTTGGACCTCTGGAAACATCAC 
Consecutive Sequence Alteration 11 AS GTGATGTTTCCAGAGGTCCAACATTACTCTGCTATC 
Consecutive Sequence Alteration 12 S  GCAGAGTAATGTTGACCCTCTGGAAACATCACTTA 
Consecutive Sequence Alteration 12 AS TAAGTGATGTTTCCAGAGGGTCAACATTACTCTGC 
Consecutive Sequence Alteration 13 S GAGTAATGTTGACCTCTTGGAAACATCACTTACAG 
Consecutive Sequence Alteration 13 AS CTGTAAGTGATGTTTCCAAGAGGTCAACATTACTC 
Consecutive Sequence Alteration 14 S GTAATGTTGACCTCTGGAAAACATCACTTACAGGGC 
Consecutive Sequence Alteration 14 AS GCCCTGTAAGTGATGTTTTCCAGAGGTCAACATTAC 
Consecutive Sequence Alteration 15 S GTTGACCTCTGGAAACCATCACTTACAGGGCTTC 
Consecutive Sequence Alteration 15 AS GAAGCCCTGTAAGTGATGGTTTCCAGAGGTCAAC 
Consecutive Sequence Alteration 16 S GACCTCTGGAAACATCCACTTACAGGGCTTC 
Consecutive Sequence Alteration 16 AS GAAGCCCTGTAAGTGGATGTTTCCAGAGGTC 
Consecutive Sequence Alteration 17 S CTCTGGAAACATCACTTTACAGGGCTTCCGGTCAA 
Consecutive Sequence Alteration 17 AS TTGACCGGAAGCCCTGTAAAGTGATGTTTCCAGAG 
Consecutive Sequence Alteration 18 S GGAAACATCACTTACCAGGGCTTCCGGTCAAAATTC 
Consecutive Sequence Alteration 18 AS GAATTTTGACCGGAAGCCCTGGTAAGTGATGTTTCC 
Consecutive Sequence Alteration 19 S GAAACATCACTTACAGGGGCTTCCGGTCAAAATTC 
Consecutive Sequence Alteration 19 AS GAATTTTGACCGGAAGCCCCTGTAAGTGATGTTTC 
Consecutive Sequence Alteration 20 S  CATCACTTACAGGGCTTTCCGGTCAAAATTCACTAG 
Consecutive Sequence Alteration 20 AS CTAGTGAATTTTGACCGGAAAGCCCTGTAAGTGATG 
Consecutive Sequence Alteration 21 S CATCACTTACAGGGCTTCCCGGTCAAAATTCACTAG 
Consecutive Sequence Alteration 21 AS CTAGTGAATTTTGACCGGGAAGCCCTGTAAGTGATG 
Consecutive Sequence Alteration 22 S CTTACAGGGCTTCCGGTTCAAAATTCACTAGGTAG 
Consecutive Sequence Alteration 22 AS CTACCTAGTGAATTTTGAACCGGAAGCCCTGTAAG 
Consecutive Sequence Alteration 23 S CTTACAGGGCTTCCGGTCAAAAATTCACTAGGTAGG  
Consecutive Sequence Alteration 23 AS CCTACCTAGTGAATTTTTGACCGGAAGCCCTGTAAG 
Consecutive Sequence Alteration 24 S GCTTCCGGTCAAAATTTCACTAGGTAGGAGGGT 
Consecutive Sequence Alteration 24 AS ACCCTCCTACCTAGTGAAATTTTGACCGGAAGC 
Consecutive Sequence Alteration 25 S CTTCCGGTCAAAATTCAACTAGGTAGGAGGGTCAT 
Consecutive Sequence Alteration 25 AS ATGACCCTCCTACCTAGTTGAATTTTGACCGGAAG 
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Primers for RT-qPCR  
Primer Name 5' to 3' sequence 
firefly S   CAACTGCATAAGGCTATGAAGAGA 
firefly AS  ATTTGTATTCAGCCCATATCGTTT 
Renilla S   AACGCGGCCTCTTCTTATTT 
Renilla AS ACCAGATTTGCCTGATTTGC 
  
   
 
